June 29th 2025
Results from Invivyd’s pemivibart (Pemgarda) phase 3 trial show it had a significant PrEP effect during the 6-month on-drug period for both immunocompromised and immunocompetent populations.
June 25th 2025
New epidemiologic data, vaccine effectiveness, and safety assessments guide a move from universal to targeted vaccination recommendations for the 2025–26 season.
June 12th 2025
Although COVID-19 has receded quite a bit from the minds of many, it still remains a virus that can present serious morbidity and mortality. Here is a review of clinical treatment strategies by an intensivist when seeing patients with severe COVID-19.
June 12th 2025
Phase 3 results show immune response and tolerability in adults 65 and older, following phase 2 findings.
May 31st 2025
The company's vaccine, mRNA-1283, becomes the first approval under the new federal guidelines.
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
A Shield of Protection: Unmet Needs in COVID-19 Prevention and Control
October 7, 2025
Register Now!
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
Canada Recommends Not Using AstraZeneca COVID-19 Vaccines in People 55 and Younger
March 30th 2021The country’s federal health agency decided upon this action based on the small number of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) incidents in Europe, which are being investigated.
Read More
New Modeling Suggests Optimal Airplane Seating to Limit COVID-19 Transmission
March 30th 2021The coronavirus disease 2019 pandemic hurt the bottom lines of airlines, as the public worried air travel would expose them to catching the virus. A new analysis suggests how airlines can best mitigate that risk.
Read More
Escalated Anticoagulation Shows No Benefit Over Standard Dosing for COVID-19 Patients in ICU
March 29th 2021Intermediate-dose prophylactic anticoagulation did not improve mortality or venous or arterial thrombosis in patients with COVID-19 in the ICU compared with standard dosing, a new study found.
Read More
2 Commerce Drive
Cranbury, NJ 08512